Eli Lilly and Company $LLY Shares Bought by Mattern Capital Management LLC

Mattern Capital Management LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 11.2% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 7,240 shares of the company’s stock after acquiring an additional 728 shares during the quarter. Mattern Capital Management LLC’s holdings in Eli Lilly and Company were worth $5,644,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in LLY. Brighton Jones LLC grew its stake in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the last quarter. Apella Capital LLC boosted its position in shares of Eli Lilly and Company by 9.4% in the 1st quarter. Apella Capital LLC now owns 1,749 shares of the company’s stock valued at $1,318,000 after purchasing an additional 151 shares during the period. Iams Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 13.9% in the 1st quarter. Iams Wealth Management LLC now owns 368 shares of the company’s stock valued at $304,000 after purchasing an additional 45 shares during the period. Finally, Clare Market Investments LLC boosted its position in shares of Eli Lilly and Company by 90.8% in the 1st quarter. Clare Market Investments LLC now owns 4,209 shares of the company’s stock valued at $3,476,000 after purchasing an additional 2,003 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.6%

LLY opened at $820.69 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The business has a 50-day moving average of $734.03 and a 200-day moving average of $766.34. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a market capitalization of $776.75 billion, a PE ratio of 53.64, a price-to-earnings-growth ratio of 1.15 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the business earned $3.92 EPS. The business’s quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other news, Director Jamere Jackson purchased 200 shares of the business’s stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $639.56 per share, with a total value of $127,912.00. Following the purchase, the director directly owned 9,402 shares of the company’s stock, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO David A. Ricks purchased 1,632 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders bought 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

LLY has been the subject of a number of recent analyst reports. UBS Group decreased their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research report on Friday, August 8th. HSBC upgraded shares of Eli Lilly and Company from a “reduce” rating to a “hold” rating and lifted their price objective for the stock from $675.00 to $700.00 in a research report on Wednesday, August 27th. JPMorgan Chase & Co. cut their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 16th. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Finally, Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 20th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $939.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.